Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Spina, Jenny Anderson, N. Archin, A. Bosque, J. Chan, M. Famiglietti, W. Greene, A. Kashuba, S. Lewin, D. Margolis, Matthew Mau, D. Ruelas, Suha Saleh, Kotaro Shirakawa, R. Siliciano, A. Singhania, P. Soto, V. Terry, E. Verdin, C. Woelk, S. Wooden, Sifei Xing, V. Planelles (2013)
An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic PatientsPLoS Pathogens, 9
Daniele Cary, K. Fujinaga, B. Peterlin (2016)
Molecular mechanisms of HIV latency.The Journal of clinical investigation, 126 2
John Bui, J. Mellors, A. Cillo (2015)
HIV-1 Virion Production from Single Inducible Proviruses following T-Cell Activation Ex VivoJournal of Virology, 90
B. Peterlin, K. Fujinaga, M. Barborič, Qintong Li, Zeping Luo, D. Price, B. Peterlin (2012)
PKC phosphorylates HEXIM1 and regulates P-TEFb activityNucleic Acids Research, 40
N. Archin, Amy Espeseth, Daniel Parker, M. Cheema, D. Hazuda, D. Margolis (2009)
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.AIDS research and human retroviruses, 25 2
D. Boehm, V. Calvanese, R. Dar, Sifei Xing, S. Schroeder, Laura Martins, K. Aull, Pao-Chen Li, V. Planelles, J. Bradner, Ming-Ming Zhou, R. Siliciano, L. Weinberger, E. Verdin, M. Ott (2013)
BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanismCell Cycle, 12
V. Quivy, E. Adam, Y. Collette, D. Demonté, A. Chariot, C. Vanhulle, B. Berkhout, R. Castellano, Y. Launoit, A. Burny, J. Piette, V. Bours, C. Lint (2002)
Synergistic Activation of Human Immunodeficiency Virus Type 1 Promoter Activity by NF-κB and Inhibitors of Deacetylases: Potential Perspectives for the Development of Therapeutic StrategiesJournal of Virology, 76
Jian Zhu, G. Gaiha, S. John, Thomas Pertel, Christopher Chin, G. Gao, Hongjing Qu, B. Walker, S. Elledge, A. Brass (2012)
Reactivation of latent HIV-1 by inhibition of BRD4.Cell reports, 2 4
K. Imai, Hiroaki Togami, T. Okamoto (2010)
Involvement of Histone H3 Lysine 9 (H3K9) Methyltransferase G9a in the Maintenance of HIV-1 Latency and Its Reactivation by BIX01294*The Journal of Biological Chemistry, 285
M. Barborič, R. Nissen, S. Kanazawa, N. Jabrane-Ferrat, B. Peterlin (2001)
NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II.Molecular cell, 8 2
K. Fujinaga, Zeping Luo, F. Schaufele, B. Peterlin (2014)
Visualization of Positive Transcription Elongation Factor b (P-TEFb) Activation in Living Cells*The Journal of Biological Chemistry, 290
D. Wei, Vicki Chiang, Elizabeth Fyne, M. Balakrishnan, Tiffany Barnes, M. Graupe, J. Hesselgesser, A. Irrinki, J. Murry, G. Stepan, Kirsten Stray, A. Tsai, Helen Yu, J. Spindler, Mary Kearney, C. Spina, D. McMahon, J. Lalezari, D. Sloan, J. Mellors, R. Geleziunas, T. Cihlář (2014)
Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical DosingPLoS Pathogens, 10
S. Trushin, G. Bren, S. Asin, K. Pennington, C. Payá, A. Badley (2005)
Human Immunodeficiency Virus Reactivation by Phorbol Esters or T-Cell Receptor Ligation Requires both PKCα and PKCθJournal of Virology, 79
U. Mbonye, J. Karn (2014)
Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure.Virology, 454-455
Y. Korin, D. Brooks, S. Brown, A. Korotzer, J. Zack (2002)
Effects of Prostratin on T-Cell Activation and Human Immunodeficiency Virus LatencyJournal of Virology, 76
Laurence Colin, C. Lint (2009)
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategiesRetrovirology, 6
Laura Diaz, M. Martínez-Bonet, J. Sánchez-Rodríguez, A. Fernández-Pineda, E. Alonso, J. Jimenez, E. Muñoz, Santiago Moreno, S. Álvarez, M. Muñoz-Fernández (2014)
Bryostatin Activates HIV-1 Latent Expression in Human Astrocytes through a PKC and NF-kB-Dependent MechanismAIDS Research and Human Retroviruses, 30
C. Lint, S. Bouchat, A. Marcello (2013)
HIV-1 transcription and latency: an updateRetrovirology, 10
Juan Palacios, Teresa Pérez-Piñar, C. Toro, Beatriz Sanz-Minguela, V. Moreno, E. Valencia, C. Gómez-Hernando, B. Rodés (2012)
Long-Term Nonprogressor and Elite Controller Patients Who Control Viremia Have a Higher Percentage of Methylation in Their HIV-1 Proviral Promoters than Aviremic Patients Receiving Highly Active Antiretroviral TherapyJournal of Virology, 86
S. Bocklandt, P. Blumberg, D. Hamer (2003)
Activation of latent HIV-1 expression by the potent anti-tumor promoter 12-deoxyphorbol 13-phenylacetate.Antiviral research, 59 2
R. Mehla, Shalmali Bivalkar-Mehla, Ruonan Zhang, I. Handy, H. Albrecht, Shailendra Giri, P. Nagarkatti, M. Nagarkatti, A. Chauhan (2010)
Bryostatin Modulates Latent HIV-1 Infection via PKC and AMPK Signaling but Inhibits Acute Infection in a Receptor Independent MannerPLoS ONE, 5
C. Bullen, G. Laird, C. Durand, J. Siliciano, R. Siliciano, R. Siliciano (2014)
Novel ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivoNature medicine, 20
S. Bouchat, N. Delacourt, A. Kula, G. Darcis, Benoit Driessche, F. Corazza, J. Gatot, A. Mélard, C. Vanhulle, K. Kabeya, Marion Pardons, V. Avettand-Fenoel, N. Clumeck, S. Wit, O. Rohr, C. Rouzioux, C. Lint (2015)
Sequential treatment with 5‐aza‐2′‐deoxycytidine and deacetylase inhibitors reactivates HIV‐1EMBO Molecular Medicine, 8
S. Matalon, B. Palmer, M. Nold, A. Furlan, A. Kassu, G. Fossati, P. Mascagni, C. Dinarello (2010)
The Histone Deacetylase Inhibitor ITF2357 Decreases Surface CXCR4 and CCR5 Expression on CD4+ T-Cells and Monocytes and is Superior to Valproic Acid for Latent HIV-1 Expression in VitroJAIDS Journal of Acquired Immune Deficiency Syndromes, 54
A. Biancotto, J. Grivel, F. Gondois-Rey, Lise Bettendroffer, R. Vigne, S. Brown, L. Margolis, I. Hirsch (2004)
Dual Role of Prostratin in Inhibition of Infection and Reactivation of Human Immunodeficiency Virus from Latency in Primary Blood Lymphocytes and Lymphoid TissueJournal of Virology, 78
G. Jiang, E. Mendes, P. Kaiser, Sumathi Sankaran-Walters, Yuyang Tang, M. Weber, G. Melcher, G. Thompson, A. Tanuri, L. Pianowski, J. Wong, S. Dandekar (2014)
Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase C&dgr;–NF-&kgr;B signalingAIDS, 28
M. Barborič, R. Nissen, S. Kanazawa, N. Jabrane-Ferrat, B. Peterlin (2001)
NF-κB Binds P-TEFb to Stimulate Transcriptional Elongation by RNA Polymerase IIMolecular Cell, 8
Blazkova (2009)
CpG methylation controls reactivation of HIV from latencyPLoS Pathog, 5
W. Bernhard, K. Barreto, A. Saunders, M. Dahabieh, Pauline Johnson, I. Sadowski (2011)
The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV‐1 without producing a T cell responseFEBS Letters, 585
J. Blazkova, K. Trejbalová, F. Gondois-Rey, Halfon Philippe, P. Patrick, E. Verdin, D. Olive, C. Lint, J. Hejnar, I. Hirsch (2010)
CpG methylation controls reactivation of HIV from latencyRetrovirology, 7
A. Cillo, M. Sobolewski, R. Bosch, Elizabeth Fyne, M. Piatak, J. Coffin, J. Mellors (2014)
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapyProceedings of the National Academy of Sciences, 111
K. Chiang, T. Sung, A. Rice (2011)
Regulation of Cyclin T1 and HIV-1 Replication by MicroRNAs in Resting CD4+ T LymphocytesJournal of Virology, 86
C. Marban, S. Suzanne, F. Dequiedt, S. Walque, L. Redel, C. Lint, D. Aunis, O. Rohr (2007)
Recruitment of chromatin‐modifying enzymes by CTIP2 promotes HIV‐1 transcriptional silencingThe EMBO Journal, 26
X. Contreras, Marc Schweneker, Ching-Shih Chen, J. McCune, S. Deeks, Jeffrey Martin, B. Peterlin (2009)
Suberoylanilide Hydroxamic Acid Reactivates HIV from Latently Infected Cells*Journal of Biological Chemistry, 284
K. Bartholomeeusen, K. Fujinaga, Yanhui Xiang, Yanhui Xiang, B. Peterlin (2013)
Histone Deacetylase Inhibitors (HDACis) That Release the Positive Transcription Elongation Factor b (P-TEFb) from Its Inhibitory Complex Also Activate HIV Transcription*The Journal of Biological Chemistry, 288
Jessica Mates, Suresh Silva, M. Lustberg, Kelsey Deusen, R. Baiocchi, Li Wu, J. Kwiek (2015)
A Novel Histone Deacetylase Inhibitor, AR-42, Reactivates HIV-1 from Chronically and Latently Infected CD4+ T-cellsRetrovirology : research and treatment, 7
G. Jiang, E. Mendes, P. Kaiser, Daniel Wong, Yuyang Tang, Ivy Cai, Anne Fenton, G. Melcher, J. Hildreth, G. Thompson, J. Wong, S. Dandekar (2015)
Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb ActivationPLoS Pathogens, 11
S. Bouchat, J. Gatot, K. Kabeya, Christelle Cardona, Laurence Colin, G. Herbein, S. Wit, N. Clumeck, O. Lambotte, C. Rouzioux, O. Rohr, C. Lint (2012)
Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1-infected HAART-treated patientsAIDS, 26
T. Sung, A. Rice (2006)
Effects of prostratin on Cyclin T1/P-TEFb function and the gene expression profile in primary resting CD4+ T cellsRetrovirology, 3
Mates (2015)
A novel histone deacetylase inhibitor, AR-42, reactivates HIV-1 from chronically and latently infected CD4 T-cellsRetrovirology (Auckl, 7
M. Hoque, R. Shamanna, Deyu Guan, T. Pe’ery, M. Mathews (2011)
HIV-1 replication and latency are regulated by translational control of cyclin T1.Journal of molecular biology, 410 5
Samuel Williams, Lin-Feng Chen, H. Kwon, D. Fenard, D. Bisgrove, E. Verdin, W. Greene (2004)
Prostratin antagonizes HIV latency by activating NF-kappaB.The Journal of biological chemistry, 279 40
Croi Livestream, Voor Toekomst, Eenmaal Daags, J. Prins, C. Boucher, J. Whitney, So-Yon Lim, C. Osuna, Srisowmya Sanisetty, Tiffany Barnes, P. Hraber, T. Cihlář (2015)
Treatment With a TLR7 Agonist Induces Transient Viremia in SIV-Infected ART- Suppressed Monkeys
The study presents the first experimental system to monitor P-TEFb activation in living cells. Since P-TEFb appears to be an essential factor toward a potent reactivation of HIV-1 gene expression
J. Blazkova, D. Murray, J. Justement, E. Funk, Amy Nelson, S. Moir, T. Chun, A. Fauci (2012)
Paucity of HIV DNA Methylation in Latently Infected, Resting CD4+ T Cells from Infected Individuals Receiving Antiretroviral TherapyJournal of Virology, 86
Gong Yang, M. Thompson, S. Brandt, S. Hiebert (2007)
Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoproteinOncogene, 26
B. Peterlin, D. Price (2006)
Controlling the elongation phase of transcription with P-TEFb.Molecular cell, 23 3
G. Laird, C. Bullen, Daniel Rosenbloom, Alyssa Martin, A. Hill, C. Durand, J. Siliciano, R. Siliciano (2015)
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.The Journal of clinical investigation, 125 5
Sona Budhiraja, M. Famiglietti, A. Bosque, V. Planelles, A. Rice (2012)
Cyclin T1 and CDK9 T-Loop Phosphorylation Are Downregulated during Establishment of HIV-1 Latency in Primary Resting Memory CD4+ T CellsJournal of Virology, 87
L. Díaz, M. Martínez-Bonet, Javier Sánchez, A. Fernández-Pineda, J. Jiménez, E. Muñoz, S. Moreno, S. Álvarez, M. Muñoz-Fernández (2015)
Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanismScientific Reports, 5
Sheena Saayman, T. Roberts, K. Morris, M. Weinberg (2015)
HIV Latency and the noncoding RNA therapeutic landscape.Advances in experimental medicine and biology, 848
Sona Budhiraja, A. Rice (2013)
Reactivation of latent HIV: do all roads go through P-TEFb?Future virology, 8 7
Richard Jones, R. O’Connor, S. Mueller, M. Foley, G. Szeto, D. Karel, M. Lichterfeld, C. Kovacs, M. Ostrowski, A. Trocha, D. Irvine, B. Walker (2014)
Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-LymphocytesPLoS Pathogens, 10
M. Jamaluddin, Pei-wen Hu, Y. Jan, E. Siwak, A. Rice (2016)
Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.AIDS research and human retroviruses, 32 2
G. Darcis, A. Kula, S. Bouchat, K. Fujinaga, F. Corazza, Amina Ait-Ammar, N. Delacourt, A. Mélard, K. Kabeya, C. Vanhulle, Benoit Driessche, J. Gatot, T. Cherrier, L. Pianowski, L. Gama, C. Schwartz, J. Vila, A. Burny, N. Clumeck, M. Moutschen, S. Wit, B. Peterlin, C. Rouzioux, O. Rohr, C. Lint (2015)
An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene ExpressionPLoS Pathogens, 11
S. Trushin, G. Bren, S. Asin, K. Pennington, C. Payá, A. Badley (2005)
Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCalpha and PKCtheta.Journal of virology, 79 15
Zichong Li, Jia Guo, Yuntao Wu, Qiang Zhou (2012)
The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivationNucleic Acids Research, 41
Samuel Williams, Lin-Feng Chen, H. Kwon, D. Fenard, D. Bisgrove, E. Verdin, W. Greene (2004)
Prostratin Antagonizes HIV Latency by Activating NF-κB*Journal of Biological Chemistry, 279
J. Kulkosky, D. Culnan, Jeanette Roman, G. Dornadula, M. Schnell, M. Boyd, R. Pomerantz (2001)
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART.Blood, 98 10
Diego José, K. Bartholomeeusen, Rodrigo Cunha, C. Abreu, J. Gliński, Thais Costa, Ana Rabay, Luiz Filho, L. Dudycz, U. Ranga, B. Peterlin, L. Pianowski, A. Tanuri, R. Aguiar (2014)
Reactivation of latent HIV-1 by new semi-synthetic ingenol esters.Virology, 462-463
(2015)
TLR7 agonist GS-9620 activates HIV1 in PBMCS from HIV-infected patients on cART
Camellia Banerjee, N. Archin, Daniel Michaels, A. Belkina, G. Denis, J. Bradner, P. Sebastiani, D. Margolis, M. Montano (2012)
BET bromodomain inhibition as a novel strategy for reactivation of HIV‐1Journal of Leukocyte Biology, 92
S. Reuse, M. Calao, K. Kabeya, Allan Guiguen, J. Gatot, V. Quivy, C. Vanhulle, Aurélia Lamine, D. Vaira, D. Demonté, V. Martinelli, E. Veithen, T. Cherrier, V. Avettand, S. Poutrel, J. Piette, Y. Launoit, M. Moutschen, A. Burny, C. Rouzioux, S. Wit, G. Herbein, O. Rohr, Y. Collette, O. Lambotte, N. Clumeck, C. Lint (2009)
Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent InfectionPLoS ONE, 4
S. Deeks (2012)
HIV: Shock and killNature, 487
S. Kauder, A. Bosque, A. Lindqvist, V. Planelles, E. Verdin (2009)
Epigenetic Regulation of HIV-1 Latency by Cytosine MethylationPLoS Pathogens, 5
G. Jiang, S. Dandekar (2015)
Targeting NF-κB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency.AIDS research and human retroviruses, 31 1
C. Abreu, Sarah Price, E. Shirk, R. Cunha, L. Pianowski, J. Clements, A. Tanuri, L. Gama (2014)
Dual Role of Novel Ingenol Derivatives from Euphorbia tirucalli in HIV Replication: Inhibition of De Novo Infection and Activation of Viral LTRPLoS ONE, 9
K. Bartholomeeusen, Yanhui Xiang, K. Fujinaga, B. Peterlin (2012)
Bromodomain and Extra-terminal (BET) Bromodomain Inhibition Activate Transcription via Transient Release of Positive Transcription Elongation Factor b (P-TEFb) from 7SK Small Nuclear Ribonucleoprotein*The Journal of Biological Chemistry, 287
K. Chiang, A. Rice (2012)
MicroRNA-Mediated Restriction of HIV-1 in Resting CD4+ T Cells and MonocytesViruses, 4
Purpose of review The ‘shock and kill’ strategy consists of activating HIV-1 expression to allow latently infected cells to die from viral cytopathic effects or host cytolytic immune effectors. This strategy relies on small molecules, called latency reversing agents, which activate HIV transcription. Recent findings Several mechanisms operating at the transcriptional level are involved in the establishment and maintenance of HIV-1 latency, including the absence of crucial inducible host transcription factors, epigenetic silencing, and the sequestration of the positive transcription elongation factor B. Progresses made toward the understanding of the molecular mechanisms of HIV-1 transcriptional repression have led to the identification of latency reversing agents that activate HIV transcription, such as histone deacetylase inhibitors or protein kinase C agonists. Multiple studies have recently pointed interesting ways to optimize the shock strategy by using combinations of latency reversing agents with an appropriate time schedule. Summary Combining latency reversing agents appears as one potential strategy for therapy against HIV-1 latency.
Current Opinion in HIV and AIDS – Wolters Kluwer Health
Published: Jul 1, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.